MOMPRUAA
MOMPRUAA
Integrated analysis of multi-omics data to establish clinical and molecular profiles predictive of the development of recurrent uveitis in patients with Ankylosing Spondylitis
Welcome to MOMPRUAA
MOMPRUAA is a national, multicenter project that aims to increase the predictive capacity to anticipate the risk of recurrent uveitis (acute anterior uveitis UAA) in patients with ankylosing spondylitis (AS).
A multiomic profile will be performed that will include the analysis of the main plasma biomarkers involved in the development and severity of uveitis and AD, and a metagenomics and metabolomics analysis to discern the involvement of the microbiome as an environmental inducer in the development of the process Bioinformatics tools will be used to establish predictive models machine learning.
Financing
Health R+D+I projects of the Carlos III Health Institute 2022. File No. PI22/01775
Development of MOMPRUAA
Main cohort
- 35 patients with HLA-B27 positive AD with recurrent UAA without biological treatment (TB)
- 35 control cohort patients with HLA-B27 positive EA without uveitis and without TB, matched by age, gender and time of disease evolution
exploratory cohort
- 10 HL-AB27-negative EA patients with recurrent UAA without TB
- 10 HLA-B27 positive EA patients with TB with relapsed UAA
- 10 HLA-B27 positive EA patients with TB without UAA
Samples to be collected within a maximum of 4 weeks after the episode of UAA
- Faeces: 2 jars, red lid jar and brown lid jar with DNA preservation
- Blood: whole blood, serum and plasma.
Exclusion criteria
- Patients under 18 years of age
- Patients who do not sign informed consent
- Patients with other chronic diseases that may affect the outcome of the study, such as immune-mediated inflammatory diseases and/or autoimmune diseases, obesity (BMI >30) diabetes, history of neoproliferative disease in the last 5 years, severe chronic kidney disease, disease severe mental and/or cognitive impairment
- Patients on biological therapy (TNFi, IL17/Il23i, JAKi) (for the main cohort)
- Patients who have received treatments or interventions that can modify the microbiome: antibiotic or probiotic treatment in the previous 3 months, having undergone a colostomy, having received preparation for colonoscopy in the previous six months, and having undergone surgeries extensive the previous month.
Participating centers
- Hospital Universitari Parc Taulí (Sabadell)
- Hospital Universitari de Vall D’Hebron (Barcelona)
- Hospital Universitari Germans Trias i Pujol (Barcelona)
- Hospital Universitari de la Santa Creu i Sant Pau (Barcelona)
- Hospital Universitario Reina Sofía (Cordoba)
- Xarxa Assistencial Universitària de Manresa (Barcelona)
- Hospital Universitario de Basurto (Bilbao)
- Hospital General de Málaga (Málaga)